article thumbnail

EC grants orphan drug designation for Precigen’s PRGN-2012

Pharmaceutical Technology

The EC has granted orphan drug designation (ODD) for Precigen's PRGN-2012 aimed at treating recurrent respiratory papillomatosis (RRP).

article thumbnail

Texas accuses Pfizer and contract manufacturer of providing ineffective ADHD drug to state's Medicaid program

Fierce Pharma

The lawsuit further accuses the companies of manipulating quality-control testing from 2012 to 2018 to ensure samples received passing grades. . | In its lawsuit, Texas says the companies knew that deficient manufacturing processes compromised the effectiveness of Quillivant XR.


Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK biotech sees worst funding downturn since 2012


Indeed, Initial Public Offerings (IPOs) raised just £28 million – the worst annual haul since 2012 – and, during the entirety of last year, UK biotech raised just £1.8 The post UK biotech sees worst funding downturn since 2012 appeared first on. billion, way down from £4.5 billion in 2021. billion raised.

Pharma 52
article thumbnail

2023 Maddox Prize Winners Announced

Copyright Clearance Center

Since 2012, the John Maddox Prize has recognized individuals who stand up for science and advance public discussions around challenging topics.

article thumbnail

Discovery mRNA manufacturing capabilities built with one thing in mind, your success.


Since 2012, we’ve been the industry leader in custom mRNA synthesis for research and clinical applications. Want to increase the probability success for your discovery mRNA program? Partner with TriLink BioTechnologies®. Read on to see how TriLink® is determined to deliver you success.

article thumbnail

The New Opportunity to Help Rare Disease Patients

MedCity News

In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5% Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025.

article thumbnail

Five Years of Forbes | Legacy MEDSearch Ranks on the Forbes Best Executive Recruitment Firms for a Fifth Consecutive Year

Legacy MEDSearch

Leadership includes Joy Celebre (recruiting since 1996, joined in 2008), Carolyn Jones (recruiting since 1995, joined in 2011), Arshad Alam (recruiting since 1995, joined 2017), John White (Talent Sourcing Manager, joined 2012), and Partner Chris Miclot, (joined 2012). “In